Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept

We received approval from an institutional review board and recruited seven unmedicated outpatients with OCD (ages 18–55) between March 2014 and March 2015, and they provided written informed consent. Patients met criteria for OCD (as defined in both DSM-IV and DSM-5) with at least moderate symptoms (score ≥16 on the Yale-Brown Obsessive Compulsive Scale [YBOCS]) (7, 8). Exclusion criteria included severe depression (score >25 on the 17-item version of the Hamilton Depression Rating Scale [HAM-D]) (9), current cognitive-behavioral therapy (CBT), and other comorbid psychiatric or general medical conditions that made participation unsafe.

Patients (N=7) received a single 3- to 5-minute intravenous push of rapastinel (10 mg/kg). At baseline, 90 minutes postinfusion, and 230 minutes postinfusion, patients self-rated the severity of their obsessions and compulsions using the YBOC Challenge Scale (10), a 10-item self-report form that assesses OCD symptoms (i.e., time spent, degree of control, severity) (total score range=0–40) over the previous 60 minutes, facilitating symptom evaluation over shorter time intervals. At the same time intervals, patients also self-rated the severity of their anxiety using the Beck Anxiety Inventory (BAI) (11) and the severity of their depression using the Beck Depression Inventory (BDI) (12). Side effects of dissociation (13), mania (14), and psychosis (15) were assessed at baseline, 90 minutes postinfusion, and 230 minutes postinfusion. At baseline and at 1 week postinfusion, an independent evaluator who was blind to study design evaluated patients using the YBOCS, which appraises obsessive and compulsive symptoms over the prior week, and patients self-rated anxiety and depression symptoms using the BAI and the BDI, respectively. Treatment response was defined a priori as a reduction of ≥35% in YBOCS scores (16). Outcomes were analyzed using a nonparametric Wilcoxon matched-pairs signed ranks test (alpha=0.05, two-tailed) without adjustment for multiple comparisons, given the exploratory nature of this study.

All seven patients who received rapastinel completed the infusion. Patients had severe OCD symptoms: the mean YBOCS score at baseline was 28.9 (SD=4.4), with a mean duration of illness of 24.9 years (SD=10.6). The mean number of prior adequate serotonin reuptake inhibitor (SRI) trials was 3.4 (SD=2.8, median=3, range=0–7). In our sample, 86% received at least one adequate trial of an SRI, 29% failed at least one prior adequate trial of antipsychotic augmentation, and 57% failed at least one prior adequate trial of CBT with exposure and response prevention. Three of the seven OCD subjects (43%) had no other psychiatric comorbidity. Two subjects (29%) met criteria for comorbid generalized anxiety disorder. Two (29%) met criteria for comorbid major depression, with baseline HAM-D scores of 11 (mild) and 14 (moderate). Compared with baseline, scores on the YBOC Challenge Scale, the BAI, and the BDI were significantly lower at 90 minutes and 230 minutes postinfusion (all p<0.05; Figure 1; see also Figure S1 in the data supplement that accompanies the online edition of this letter); the percentage decrease in YBOC Challenge Scale scores from baseline to 230 minutes postinfusion was 46.4%. OCD severity, as measured by the YBOCS, was not significantly decreased from baseline to 1 week postinfusion, and neither were scores on the BDI, although scores on the BAI were significantly decreased (p=0.02). No patient met the treatment response criterion (reduction of ≥35% in the YBOCS score) at 1 week postinfusion (the mean YBOCS score at baseline was 28.9 [SD=4.4] and was 26.0 [SD=5.4] at 1 week postinfusion). One individual with mild comorbid depression had a further reduction in HAM-D scores, from 11 (at baseline) to 1 (at 230 minutes), with a slight increase to 7 (by 1 week after infusion of rapastinel).

Rapastinel was well tolerated. Of note, in contrast to participant reports in a prior study of intravenous ketamine in OCD (1), participants did not report adverse events (e.g., dizziness, nausea, vomiting, or headache). Assessments of dissociation, mania, and psychosis were not significantly changed from baseline.

The findings suggest that rapastinel is well tolerated in unmedicated OCD patients, as it is in patients with depression (6). Specifically, rapastinel did not increase psychotomimetic effects following dosing in this sample of OCD patients, unlike ketamine in prior studies (1, 3–5). In this small open-label sample, rapastinel had acute effects on obsessions and compulsions and on symptoms of anxiety and depression. However, rapastinel did not have significant effects on OCD symptoms 1 week postinfusion. To have clinical utility, glutamate modulators should refine molecular targets for rapid and sustained action while minimizing side effects. Mechanistic preclinical data suggest drugs like rapastinel (17) and ketamine’s metabolite hydroxynorketamine (1, 18) that act on AMPA receptor modulation pathways may be promising therapeutic strategies.

The authors thank the individuals who generously donated their time to participate in this study.